ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 47 for:    "Dyslexia"

Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00111371
Recruitment Status : Unknown
Verified September 2006 by University Hospital Muenster.
Recruitment status was:  Recruiting
First Posted : May 20, 2005
Last Update Posted : December 5, 2014
Sponsor:
Information provided by:
University Hospital Muenster

Brief Summary:
This study aims to determine whether levodopa, in combination with a high frequency training of (grammatical) rules, is effective in boosting learning success in healthy subjects and whether this kind of training in combination with levodopa improves reading and spelling abilities of patients with dyslexia.

Condition or disease Intervention/treatment Phase
Dyslexia Drug: Levodopa Phase 4

Detailed Description:
Prior work by our group shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind trial, we probe whether daily administration of levodopa, coupled with a training of grammatical rules, improves the training success in healthy adults as compared to placebo administration. In the second step of this study, patients with dyslexia will be trained with the identical protocol. We postulate that the combination of intensive training in language rules and levodopa improves the reading, writing, and spelling abilities of patients with dyslexia.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dyslexia)
Study Start Date : January 2005
Estimated Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Memory
Drug Information available for: Levodopa




Primary Outcome Measures :
  1. Boost in training success (percent correct) through levodopa as compared to placebo
  2. Boost in training success (reaction times) through levodopa as compared to placebo
  3. Increased performance on reading, spelling and writing tests in dyslexic patients treated with levodopa as compared to placebo

Secondary Outcome Measures :
  1. Stability of improvements one month post training


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Right-handedness
  • Age between 18-35 years
  • Primary language: German

Exclusion Criteria:

  • Known allergy to levodopa or tetrazine
  • History of medication/drug abuse
  • Acute nicotine withdrawal or > 10 cigarettes per day
  • >6 cups/glasses of coffee, caffeine drinks or energy drinks per day
  • >50 grams of alcohol per day
  • Hypertonia
  • Arteriosclerosis
  • Diabetes, asthma, or glaucoma
  • Psychiatric disease
  • Neurologic disease
  • Other medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00111371


Contacts
Contact: Stefan Knecht, MD +49-251-83 ext 48195 knecht@uni-muenster.de

Locations
Germany
Dept. of Neurology, University Hospital of Muenster Recruiting
Muenster, North-Rhine Westphalia, Germany, 48129
Contact: Stefan Knecht, Prof. Dr.    +49-251-83 ext 48195    knecht@uni-muenster.de   
Principal Investigator: Stefan Knecht, M.D.         
Sponsors and Collaborators
University Hospital Muenster
Investigators
Principal Investigator: Stefan Knecht, Prof. Dr. Dept. of Neurology, Universityclinic of Muenster

Publications:
ClinicalTrials.gov Identifier: NCT00111371     History of Changes
Other Study ID Numbers: LL-001; Project on Dyslexia
First Posted: May 20, 2005    Key Record Dates
Last Update Posted: December 5, 2014
Last Verified: September 2006

Keywords provided by University Hospital Muenster:
artificial grammar learning
dyslexia
healthy subjects
levodopa
drug
treatment
intervention

Additional relevant MeSH terms:
Dyslexia
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Learning Disorders
Signs and Symptoms
Neurodevelopmental Disorders
Mental Disorders
Levodopa
Dopamine
Dopamine Agents
Dopamine Agonists
Antiparkinson Agents
Anti-Dyskinesia Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Cardiotonic Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Protective Agents